共 50 条
- [31] Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I studyANNALS OF ONCOLOGY, 2024, 35 : S495 - S495Simonelli, M.Lorusso, D.Homicsko, K.Seguy, F.Kinder, M.Liu, Q.Croft, E.Kitano, S.
- [32] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2016, 78 : 405 - 417Klaus MrossHeike RichlyAnnette FrostDirk ScharrBahar NokayRalph GraeserChooi LeeJames HilbertRainer-George GoeldnerOliver FietzMax E. Scheulen
- [33] Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I studyONCOTARGET, 2017, 8 (26) : 42076 - 42086Xu, Jian MingWang, YanChen, Yu LingJia, RuLi, JieGong, Ji FangLi, JingQi, ChuanHua, YeTan, Cui RongWang, JianLi, KeSai, YangZhou, FengRen, Yong XinQing, Wei GuoJia, HongSu, Wei GuoShen, Lin
- [34] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumorsCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 405 - 417Mross, KlausRichly, HeikeFrost, AnnetteScharr, DirkNokay, BaharGraeser, RalphLee, ChooiHilbert, JamesGoeldner, Rainer-GeorgeFietz, OliverScheulen, Max E.
- [35] A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2015, 21 (05) : 1044 - 1051Wagner, Andrew J.Messersmith, Wells A.Shaik, M. NaveedLi, SherryZheng, XianxianMcLachlan, Karen R.Cesari, RossanoCourtney, RachelLevin, Wendy J.El-Khoueiry, Anthony B.
- [36] Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Moore, Kathleen N.Jones, Suzanne FieldsKurkjian, CarlaArkenau, Hendrik-TobiasInfante, Jeffrey R.Pant, ShubhamBurris, Howard A.McMeekin, D. ScottGibbons, JayHarrow, KimberlyLiang, ChrisRamsey, SaraBendell, Johanna C.
- [37] A clinical phase I and biomarker study of the Raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2002, 38 : S53 - S54Strumberg, DVoliotis, DMoeller, JGHilger, RARichly, HBeling, CTewes, MSchleucher, NScheulen, MESeeber, S
- [38] A Phase I Study of dasatinib, a SRC and multi-kinase inhibitor, in patients (pts) with GIST and other solid tumorsEJC SUPPLEMENTS, 2006, 4 (12): : 118 - 118Morgan, J.Demetri, G.Wang, D.MacPherson, I.LoRusso, P.van den Abbeele, A.Brunton, V.Luo, R.Voi, M.Evans, T.
- [39] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumorsInvestigational New Drugs, 2020, 38 : 1755 - 1762Mojun ZhuJulian R. MolinaGrace K. DyGary A. CroghanYingwei QiJames GlocknerLorelei J. HansonMichelle M. RoosAngelina D. TanAlex A. Adjei
- [40] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1755 - 1762Zhu, MojunMolina, Julian R.Dy, Grace K.Croghan, Gary A.Qi, YingweiGlockner, JamesHanson, Lorelei J.Roos, Michelle M.Tan, Angelina D.Adjei, Alex A.